platensimycin

has antidiabetic and antisteatotic activities; a pentacyclic ketolide (structurally similar to adamantane) connected by an amide bond to 3-amino-2,4-dihydroxybenzoic acid; inhibits cellular lipid biosynthesis; discovered while screening compounds from Streptomyces platensis bacteria in a South African soil sample with S. aureus bacteria deficient in FabF protein; structure in first source

Also Known As:

Networked: 14 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Duan, Yanwen: 5 articles (12/2021 - 02/2017)
2.	Huang, Yong: 5 articles (12/2021 - 02/2017)
3.	Singh, Sheo B: 4 articles (01/2017 - 05/2006)
4.	Su, Meng: 3 articles (12/2021 - 01/2019)
5.	Wang, Zhe: 3 articles (12/2021 - 01/2020)
6.	Shen, Ben: 3 articles (01/2020 - 02/2017)
7.	Herath, Kithsiri: 3 articles (01/2017 - 05/2006)
8.	Li, Cai: 3 articles (01/2017 - 03/2011)
9.	Miller, Corey: 3 articles (01/2017 - 03/2011)
10.	Wu, Margaret: 3 articles (01/2017 - 03/2011)

Related Diseases

1.	Infections 01/01/2022 - "Platensimycin and surfactin were comprehensively studied to combat prevalent MRSA skin infection. " 01/01/2022 - "The combination of effective and biosafe surfactin and platensimycin could be a promising and efficient treatment for MRSA skin infection, which could provide a feasible solution to combat the major global health threats caused by MRSA." 11/01/2021 - "Platensimycin (PTM) is a natural drug lead that targets bacterial fatty acid synthases and has a great potential to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). " 11/01/2021 - "Nanoparticle-Hydrogel Systems Containing Platensimycin for Local Treatment of Methicillin-Resistant Staphylococcus aureus Infection." 01/01/2019 - "Evaluation of Platensimycin and Platensimycin-Inspired Thioether Analogues against Methicillin-Resistant Staphylococcus aureus in Topical and Systemic Infection Mouse Models."
2.	Insulin Resistance 01/01/2017 - "Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys." 01/01/2016 - "The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys." 03/29/2011 - "Chronic administration of platensimycin led to a net reduction in liver triglyceride levels and improved insulin sensitivity in db/+ mice fed a high-fructose diet. "
3.	Fatty Liver 09/01/2014 - "(-)-Platensimycin is a potent inhibitor of fatty acid synthase that holds promise in the treatment of metabolic disorders (e.g., diabetes and "fatty liver") and pathogenic infections (e.g., those caused by drug-resistant bacteria). " 01/01/2017 - "Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys." 01/01/2016 - "The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys."
4.	Non-alcoholic Fatty Liver Disease 12/21/2021 - "Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model."
5.	Staphylococcal Infections 05/18/2006 - "Treatment with platensimycin eradicates Staphylococcus aureus infection in mice. "

Related Drugs and Biologics

1.	Fatty Acid Synthases (Fatty Acid Synthase)
2.	Lipopeptides
3.	Therapeutic Uses
4.	Triglycerides (Triacylglycerol)
5.	Fructose
6.	Anti-Bacterial Agents (Antibiotics)
7.	Hydrogels
8.	Sulfides (Thioethers)
9.	Solutions
10.	Sulfasalazine (Azulfidine)